

Special Issue

Cancer Challenges during COVID-19 Pandemic

Message from the Guest Editors

The COVID-19 pandemic, which presented a greater risk of severe morbidity in older and fragile patients, resulted in higher mortality for people with chronic diseases (particularly cardiovascular disease and diabetes) and cancer, highlighting the weakness of many welfare systems all over the world. Most responsive cancer institutes have had to redesign their strategies to continue their activities. In particular, new therapeutic protocols and follow-up procedures have been implemented. Patients have had to be carefully evaluated to plan the optimal personalized treatment and to adopt the most appropriate therapeutic strategies, including telemedicine and digital monitoring. Healthcare professionals have had to be monitored for exposure to SARS-CoV-2 using genetic/antigen diagnostic kits and serological tests and, most recently, have been vaccinated with one of the several—not yet fully studied—available vaccines.

Guest Editors

Dr. Franco M. Buonaguro

Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy

Dr. Attilio AM Bianchi

Ist Nazl Tumori, IRCCS, Fdn G Pascale, I-80131 Naples, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/79540

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).